liberals FOOLED by Elon’s shocking surprise

Elon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the liberals broke”... But it turns out that was all just a smokescreen to hide the TRUTH…

Click here to discover the real reason Elon Musk became buddy-buddy with Trump.

Yakob Liawatidewi net worth and biography

Yakob Liawatidewi Biography and Net Worth

EVP of Amphastar Pharmaceuticals

Jacob Liawatidewi, M.B.A., has served as Executive Vice President of Corporate Administration Center and Sales and Marketing since May 2020, and President of Amphastar France Pharmaceuticals since December 2020 (Amphastar subsidiary), and as Senior Vice President of Corporate Administration Center since March 2014, Corporate Secretary since June 2013, and Senior Vice President of Sales and Marketing since December 2013. Mr. Liawatidewi served as Vice President of Sales and Marketing from August 2012 until his promotion to Senior Vice President. From August 2005 to August 2012, Mr. Liawatidewi was the company’s Associate Vice President of Sales and Marketing. Since joining the company in June 1997 to August 2005, Mr. Liawatidewi held various roles in the company’s business development, sales, and marketing department. Mr. Liawatidewi received a B.S. in Biology from California State University of Fresno in 1996 and an M.B.A. from the National University in 2014.

What is Yakob Liawatidewi's net worth?: The estimated net worth of Yakob Liawatidewi is at least $2.87 million as of November 6th, 2024. Mr. Liawatidewi owns 74,938 shares of Amphastar Pharmaceuticals stock worth more than $2,867,877 as of December 26th. This net worth estimate does not reflect any other assets that Mr. Liawatidewi may own. Learn More about Yakob Liawatidewi's net worth.
How do I contact Yakob Liawatidewi?: The corporate mailing address for Mr. Liawatidewi and other Amphastar Pharmaceuticals executives is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. Amphastar Pharmaceuticals can also be reached via phone at (909) 980-9484 and via email at [email protected]. Learn More on Yakob Liawatidewi's contact information.
Has Yakob Liawatidewi been buying or selling shares of Amphastar Pharmaceuticals?: Over the course of the past ninety days, Yakob Liawatidewi has sold $271,388.70 in Amphastar Pharmaceuticals stock. Most recently, Yakob Liawatidewi sold 5,214 shares of the business's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a transaction totalling $271,388.70. Following the completion of the sale, the executive vice president now directly owns 74,938 shares of the company's stock, valued at $3,900,522.90. Learn More on Yakob Liawatidewi's trading history.
Who are Amphastar Pharmaceuticals' active insiders?: Amphastar Pharmaceuticals' insider roster includes Diane Gerst (Director), Richard Koo (Director), Howard Lee (Director), Yakob Liawatidewi (EVP), Mary Luo (COO), Ziping Luo (Chairman), William Peters (CFO), Floyd Petersen (Director), Richard Prins (Director), Michael Zasloff (Director), Jack Zhang (CEO), Yongfeng Zhang (Co-Founder), and Rong Zhou (EVP). Learn More on Amphastar Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Amphastar Pharmaceuticals?: In the last year, insiders at the sold shares 21 times. They sold a total of 363,042 shares worth more than $19,564,696.71. The most recent insider tranaction occured on December, 12th when EVP Rong Zhou sold 7,000 shares worth more than $310,940.00. Insiders at Amphastar Pharmaceuticals own 27.1% of the company. Learn More about insider trades at Amphastar Pharmaceuticals.
Information on this page was last updated on 12/12/2024.

Yakob Liawatidewi Insider Trading History at Amphastar Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/6/2024	Sell	5,214	$52.05	$271,388.70	74,938
8/28/2023	Sell	28,816	$53.13	$1,530,994.08	69,669
4/13/2023	Sell	11,494	$41.56	$477,690.64	69,215
4/10/2023	Sell	5,000	$40.00	$200,000.00	69,215
8/9/2022	Sell	3,055	$39.00	$119,145.00	61,607
7/15/2022	Sell	10,837	$36.64	$397,067.68	61,607
7/15/2021	Sell	31,524	$20.01	$630,795.24	77,927
5/11/2021	Sell	10,000	$19.06	$190,600.00	71,351
7/21/2020	Sell	5,978	$21.22	$126,853.16	50,182
6/9/2020	Sell	23,405	$20.12	$470,908.60	69,529
9/13/2019	Sell	3,000	$21.45	$64,350.00	33,670
9/5/2019	Sell	1,515	$21.24	$32,178.60	36,670
8/13/2019	Sell	5,000	$20.73	$103,650.00	47,188
2/14/2019	Sell	8,868	$23.86	$211,590.48	39,883
2/12/2019	Sell	4,000	$23.70	$94,800.00	39,883
2/5/2019	Sell	11,397	$23.18	$264,182.46	47,280
1/23/2019	Sell	7,000	$22.52	$157,640.00	40,463
1/16/2019	Sell	3,183	$22.15	$70,503.45	37,471
1/14/2019	Sell	8	$22.15	$177.20	37,471
11/30/2018	Sell	13,980	$21.50	$300,570.00	48,963
11/28/2018	Sell	1,520	$20.49	$31,144.80	37,463
11/23/2018	Sell	1,299	$20.26	$26,317.74	37,463
11/9/2018	Sell	17,808	$20.97	$373,433.76	46,763

Yakob Liawatidewi Buying and Selling Activity at Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Company Overview

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Today's Range

Now: $38.19

$37.81

$38.60

50 Day Range

MA: $46.04

$38.27

$53.40

2 Week Range

Now: $38.19

$36.56

$65.92

Volume

98,654 shs

Average Volume

414,062 shs

Market Capitalization

$1.84 billion

P/E Ratio

12.73

Dividend Yield

N/A

Beta

0.78